Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel

10 About this resource

The NICE Health Technologies Adoption Programme produces practical advice on adopting health technologies in the NHS in England.

NICE's Health Technologies Adoption Programme recruited, selected and worked with 2 NHS organisations to share their experience of using faecal calprotectin testing with organisations that may wish to use it in the future. The information gained from these NHS organisations and included in this resource is intended for the sole purpose of supporting the NHS in adopting or researching faecal calprotectin testing.

The information was not assessed by the Independent External Assessment Group or considered by the Diagnostics Advisory Committee when making its decision on the use of faecal calprotectin testing as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered.

This resource accompanies the NICE diagnostics guidance on faecal calprotectin diagnostics tests for inflammatory diseases of the bowel. It was developed using the NICE Health Technologies Adoption Programme process. It is an implementation tool that discusses and summarises the experiences reported by staff at NHS sites who have previously adopted this technology, and it shares the learning that took place.

Implementation of the guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this document should be interpreted in a way that would be inconsistent with compliance with those duties.

ISBN: 978-1-4731-1332-9